Literature DB >> 30681722

Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma.

Julia Paczkowska1, Natalia Soloch1, Magdalena Bodnar2,3, Katarzyna Kiwerska1,4, Joanna Janiszewska1, Julia Vogt5, Ewa Domanowska2, José I Martin-Subero6, Ole Ammerpohl5,7, Wolfram Klapper8, Andrzej Marszalek9, Reiner Siebert5,7, Maciej Giefing1,7.   

Abstract

Loss of B cell-specific transcription factors (TFs) and the resulting loss of B-cell phenotype of Hodgkin and Reed-Sternberg (HRS) cells is a hallmark of classical Hodgkin lymphoma (cHL). Here we have analysed two members of ETS domain containing TFs, ELF1 and ELF2, regarding (epi)genomic changes as well as gene and protein expression. We observed absence or lower levels of ELF1 protein in HRS cells of 31/35 (89%) cases compared to the bystander cells and significant (P < 0·01) downregulation of the gene on mRNA as well as protein level in cHL compared to non-cHL cell lines. However, no recurrent loss of ELF2 protein was observed. Moreover, ELF1 was targeted by heterozygous deletions combined with hypermethylation of the remaining allele(s) in 4/7 (57%) cell lines. Indeed, DNA hypermethylation (range 95-99%, mean 98%) detected in the vicinity of the ELF1 transcription start site was found in all 7/7 (100%) cHL cell lines. Similarly, 5/18 (28%) analysed primary biopsies carried heterozygous deletions of the gene. We demonstrate that expression of ELF1 is impaired in cHL through genetic and epigenetic alterations, and thus, it may represent an additional member of a TF network whose downregulation contributes to the loss of B-cell phenotype of HRS cells.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990ELF1zzm321990; zzm321990ELF2zzm321990; classical Hodgkin lymphoma; loss of B-cell identity; transcription factors

Mesh:

Substances:

Year:  2019        PMID: 30681722     DOI: 10.1111/bjh.15757

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.

Authors:  Suraya Elfrink; Martin Ter Beest; Luuk Janssen; Marijke P Baltissen; Pascal W T C Jansen; Angelique N Kenyon; Raymond M Steen; Daynelys de Windt; Philipp M Hagemann; Corine Hess; Dick-Johan van Spronsen; Brigiet Hoevenaars; Ellen van der Spek; Zijun Y Xu-Monette; Ken H Young; Charlotte Kaffa; Sander Bervoets; Jolien van Heek; Eva Hesius; Charlotte M de Winde; Michiel Vermeulen; Michiel van den Brand; Blanca Scheijen; Annemiek B van Spriel
Journal:  Blood Adv       Date:  2022-04-12

2.  Integrative genome-wide chromatin accessibility and transcriptome profiling of diffuse large B-cell lymphoma.

Authors:  Ying Fang; Mu-Chen Zhang; Peng-Peng Xu; Su-Jiang Zhang; Li Wang; Shu Cheng; Di Fu; Chun-Kang Chang; Xiao-Jian Sun; Yan Zhao; Yi-Jia Tang; Xin Tian; Hong-Mei Yi; Feng Liu; Wei-Li Zhao
Journal:  Clin Transl Med       Date:  2022-07

3.  Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.

Authors:  Armando N Bastidas Torres; Davy Cats; Jacoba J Out-Luiting; Daniele Fanoni; Hailiang Mei; Luigia Venegoni; Rein Willemze; Maarten H Vermeer; Emilio Berti; Cornelis P Tensen
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.